Skip to content
Screener

Lexicon Pharmaceuticals LXRX Q4 2025 Annual earnings

Reported March 5, 2026 · Before market open

Revenue$5.5MBeat by $2.4M
EPS-$0.04Beat by $0.03
Revenue estimate$3.1M
EPS estimate-$0.07

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.8M
EPS estimate-$0.06

Financials

Q4 2025

Income statement

See full
Revenue$5.5M-79.3%
Gross profit$5.3M-79.8%
Operating income-$14.8M+54.9%
Net income-$15.5M+54.0%
EPS (diluted)-$0.04+55.6%

Balance sheet

See full
Cash & equivalents$63.3M-5.0%
Total debt$62.2M-41.3%
Total equity$107.5M-26.3%
Total assets$185.0M-38.0%

Cash flow

See full
Operating cash flow-$17.2M+19.8%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$417.91M+56.5%
Enterprise value$416.82M+36.0%
P/S8.4×-0.2×

Profitability

See full
Gross margin99.4%+1.4pp
Operating margin-98.2%-45.0pp
Net margin-101.1%-46.2pp

Returns & leverage

See full
Return on equity-39.7%-17.2pp
Debt / equity0.6×-0.1×
Current ratio4.9×-0.6×

Segments

By segment

See full
Reportable Segment$5.5M-79.3%

By product

See full
License$4.3M-82.8%

FAQ

When did Lexicon Pharmaceuticals report Q4 2025 earnings?
Lexicon Pharmaceuticals (LXRX) reported Q4 2025 earnings on March 5, 2026 before market open.
What were Lexicon Pharmaceuticals's Q4 2025 revenue and EPS?
Lexicon Pharmaceuticals reported revenue of $5.5M and eps of $-0.04 for Q4 2025.
Did Lexicon Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $3.1M by $2.4M. EPS beat the consensus estimate of $-0.07 by $0.03.
How did Lexicon Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 79.3% from $26.6M a year earlier and eps grew 55.6% from $-0.09.
Where can I find Lexicon Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001062822-26-000047) and the 10-K periodic report (0001062822-26-000050) directly on SEC EDGAR. The filing index links above go to sec.gov.